Form 4: Enzo Biochem Director Bradley Louis Radoff Acquires Shares Through Restricted Stock Units

Director Bradley Louis Radoff of Enzo Biochem acquired 142,897 shares through restricted stock units, increasing his total holdings.

Summary

• Bradley Louis Radoff, a director at Enzo Biochem, acquired 142,897 shares of common stock through restricted stock units.
• These restricted stock units will fully vest on the earlier of January 16, 2026, or a change of control event.
• The transaction occurred on January 16, 2025, and the shares were acquired at a price of $0.
• Following the transaction, Radoff directly owns 4,533,779 shares of Enzo Biochem common stock.
• Radoff also indirectly owns 430,000 shares through The Radoff Family Foundation.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects an insider increasing their stake in the company, which is generally seen as a sign of confidence. However, it is a routine transaction.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The restricted stock units will vest on the earlier of January 16, 2026, or a change of control event.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting changes in their beneficial ownership of company stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Similar filings are common across all publicly traded companies in the US.
• The acquisition of shares through restricted stock units is a typical form of compensation for directors and executives.
• The reporting requirements are standardized by the SEC, ensuring transparency and comparability across companies.

Stakeholder Impact

• The transaction may have a slightly positive impact on shareholder sentiment as it indicates a director's confidence in the company.

Key Dates

Keywords

Enzo Biochem, Bradley Louis Radoff, restricted stock units, share acquisition, insider trading, director, equity